Reata Pharmaceuticals — Q1 2023 Earnings Presentation
36 slides from Reata Pharmaceuticals's earnings presentation, May 10, 2023
Slide 1: 1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs
1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs May 10, 2023 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain “forward‐looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward‐looking statements, including statements reg
Slide 3: Today's Agenda
Today’s Agenda Opening Remarks | Warren Huff, CEO U.S. Commercial Update | Dawn Bir, Chief Commercial Officer Regulatory Update | Andrea Loewen, SVP, Regulatory Affairs Development Update | Seemi Khan, Chief Medical Officer Development Update | Colin Meyer, Chief Innovation Officer Operational & Fin
Slide 4: SKYCLARYS Approval
SKYCLARYS® Approval 1SKYCLARYS® (omaveloxolone) See Full Prescribing information; FDA: U.S. Food and Drug Administration; FA: Friedreich’s ataxia; HCP: Health care provider; PK: Pharmacokinetics; EMA: European Medicines Agency SKYCLARYS is the first and only FDA approved therapy indicated for patien
Slide 5: Neurology Pipeline Updates
Neurology Pipeline Updates MAA: Marketing Authorization Application; Nrf2: Nuclear factor-erythroid factor 2-related factor 2; DPNP: Diabetic Peripheral Neuropathic Pain MAA for omaveloxolone for patients with FA in Europe submitted in Q4 2022 Received Day 120 List of Questions (LOQ) On track to sub
Slide 6: Bardoxolone and Corporate Updates
Bardoxolone and Corporate Updates ESRD: End-stage renal disease; CKD: Chronic kidney disease Kyowa Kirin reported results from AYAME, Phase 3 trial of bardoxolone in patients with diabetic kidney disease Met primary and key secondary endpoints with no significant safety issues No separation in ESRD
Slide 7: U.S. Commercial Update
U.S. Commercial Update
Slide 8: U.S. Market Opportunity and HCP Launch Landscape
U.S. Market Opportunity and HCP Launch Landscape 1CCRN: Collaborative Clinical Research Network in Friedreich’s ataxia, https://curefa.org/network; ; 2https://www.ataxia.org/neurologists-and-specialty-clinics/; 32023 FA Claims analysis; 4NIH Friedreich Ataxia Fact Sheet (Accessed 2/2023); 5Estimated
Slide 9: U.S. Early Demand Reflects Engaged HCPs and Patients
U.S. Early Demand Reflects Engaged HCPs and Patients Patient and HCP communities have awaited a treatment for FA ~500 Patient Start Forms Received by Reata REACH patient services SKYCLARYS Launch Performance Through May 10 SKYCLARYS Payer Coverage Progressing as Expected Payer approval for coverage
Slide 10: 2023 U.S. Launch Commercial Strategy
2023 U.S. Launch Commercial Strategy Establish SKYCLARYS as the first effective and safe treatment approved for Friedreich’s ataxia Communicate the value of SKYCLARYS to HCPs who treat FA Activate FA patients to proactively seek SKYCLARYS treatment Facilitate coverage, access and affordability 1 2 3
Slide 11: U.S. Market Access and Sales Force Execution
U.S. Market Access and Sales Force Execution Neurology Sales Force Patient Access Team Our Field Sales Team: ~2,500 U.S. HCP Targets Deployed fully trained and experienced U.S. field sales team March 6th ~2,500 sales force target HCPs treat the majority of diagnosed U.S. Friedreich's ataxia patients
Slide 12: Regulatory Update
> = " [s Regulatory > ve Update sss REATA. ee @ rhanwaceuticats
Slide 13: SKYCLARYS Drug Availability
SKYCLARYS Drug Availability NDA supplement submitted in Q2 2023 to add a limit to the drug substance specification for a process impurity observed above the approved specification for unspecified impurities during commercial scale API validation SKYCLARYS drug product manufacturing and testing succe
Slide 14: FDA Review Considerations
FDA Review Considerations NDA Supplement Low safety risk Limit below the FDA Qualification Threshold? Detectable? Structure identified? No impact on total impurities? Physical properties unchanged? FDA assesses each impurity specification on a case-by-case basis to determine the potential impact of
Slide 15: Omaveloxolone MAA Status
Omaveloxolone MAA Status CMC: Chemistry, manufacturing, and controls MAA submitted in Europe for omaveloxolone for the treatment of Friedreich’s ataxia in Q4 2022 Received Day 120 List of Questions (LOQ) Primary feedback mechanism regarding EMA’s review of the MAA Day 120 responses primary mechanism
Slide 16: Pediatric Expansion Plans
Pediatric Expansion Plans sss REATA. eco OOO rictwcceuticacs
Slide 17: Omaveloxolone Plans for Pediatric Studies in FA
Omaveloxolone Plans for Pediatric Studies in FA PIP: Pediatric investigation plan Evaluating strategies to support global label expansion for pediatric patients Pediatric development plans in Europe Received positive opinion on PIP from the Pediatric Committee Based on agreement in the PIP, request
Slide 18: Neurology Pipeline Updates
Neurology Pipeline Updates Ses es
Slide 19: Nrf2 Activator Pharmacology May be Applicable to a Broad Set of Neurological Diseases
Mitochondrial dysfunction, neuroinflammation, and neurodegeneration are common features of neurological diseases Genetic or pharmacologic activation of Nrf2 has demonstrated activity in multiple preclinical models that demonstrate effects on: Mitochondrial function Neuroinflammation Neurodegeneratio
Slide 20: Overview & Status of Next Generation Nrf2 Activator Program
Overview & Status of Next Generation Nrf2 Activator Program ADME: absorption, distribution, metabolism, and excretion; PK: Pharmacokinetics; IND: Investigational New Drug Application Have advanced two next generation Nrf2 activators, RTA 415 and RTA 417, to IND-directed studies Structure-activity re
Slide 21: Cemdomespib: Hsp90 Modulator for DPNP
Cemdomespib: Hsp90 Modulator for DPNP Cemdomespib (RTA 901) is a highly potent and selective, oral, small-molecule modulator of Hsp90 Differentiated from N-terminal Hsp90 inhibitors and promotes mitochondrial function Active in preclinical models of painful and insensate diabetic neuropathy1 DPNP is
Slide 22: Cemdomespib: Phase 2 Trial Design
Cemdomespib: Phase 2 Trial Design Randomized, double-blind, placebo-controlled, two-part, 12-week Phase 2 trial of cemdomespib in patients with DPNP Objective is to assess pain using the numeric pain rating scale (NPRS) Plan to enroll 192 patients in each of Part 1 and Part 2 Patients allowed to tak
Slide 23: Bardoxolone Update
Bardoxolone Update
Slide 24: AYAME Purpose and Design
AYAME Purpose and Design Conducted to determine if eGFR improvements translate to reductions in ESRD Phase 3, randomized, double-blind, placebo-controlled trial in diabetic kidney disease Enrolled patients with advanced CKD (eGFR of ≥15.0 to <60.0 mL/min/1.73 m2) Treatment duration of 3 to 4 years w
Slide 25: AYAME Efficacy Results
AYAME Efficacy Results Primary and key secondary composite endpoints demonstrated statistical significance favoring bardoxolone Driven by reductions in 30% and 40% eGFR decline events No separation in ESRD events AYAME data showing improvements in eGFR-based endpoints without a trend in ESRD pose a
Slide 26: AYAME Safety Overview
Safety data provide important data for the broader Nrf2 activator class Renal safety: no evidence of hyperfiltration or adverse renal safety CV safety: no evidence of adverse CV safety with no imbalances in Deaths Adjudicated CV events SAEs Fluid overload events Blood pressure Liver safety: no evide
Slide 27: Operational and Financial Updates
Operational and Financial Updates
Slide 28: Operational Update
Operational Update Drug product manufacturing completed Packaging and labeling of SKYCLARYS bottles completed Anticipate SKYCLARYS commercial drug supply availability through the specialty pharmacy no later than mid-August 2023, subject to regulatory approval Ramped up production activities for the
Slide 29: EU Update
EU Update Continuing build-up of our EU infrastructure following submission of our MAA for omaveloxolone in Q4 2022 Hired EU headquarter leadership team: commercial, marketing, market access, medical affairs, and supply chain activities Initiated marketing activities, global value messaging, and hea
Slide 30: BXLS Amendment Update
BXLS Amendment Update BXLS: Blackstone Life Sciences Amended BXLS development agreement Removes all obligations for bardoxolone development and commercialization Removes restrictions on any new debt Removes restrictions on licensing any assets Released all prior security interests granted to BXLS Pr
Slide 31: Financial Update
Financial Update Completed $275 million debt financing agreement Initial tranche of $75 million to be funded on May 12, 2023 Second tranche of $50 million after meeting certain regulatory or production requirements Two final tranches of $75 million each to be borrowed based on commercial sales miles
Slide 32: Financial Summary
Financial Summary 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAAP and non-GAAP measures. GAAP: G
Slide 33: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 34: Concluding Remarks
Concluding Remarks
Slide 35: Reata at a Glance
Reata at a Glance With SKYCLARYS approval Reata is transitioning into a commercial enterprise Encouraging initial demand from patients and HCPs Drug availability expected no later than mid-August 2023 MAA for omaveloxolone under review in the EU Phase 2 trial of cemdomespib in patients with DPNP ant
Slide 36: Thank you
k you J \ yuu /
Reata Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix